| 1 | Vedolizumab | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab [20] Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Mln0002 (vedolizumab); Vedolizumab; Vedolizumab (genetical recombination); Vedolizumab 108 mg sc; Vedolizumab 300 mg; Vedolizumab 300 mg injection [entyvio]; Vedolizumab 300 mg iv; Vedolizumab injection; Vedolizumab intravenous (iv), vedolizumab subcutaneous (sc), placebo iv; Vedolizumab intravenous injection; Vedolizumab iv; Vedolizumab iv (entyvio™); Vedolizumab iv 300 mg; Vedolizumab iv, placebo iv, placebo sc; Vedolizumab iv, placebo sc; Vedolizumab sc; Vedolizumab sc 108 mg; Vedolizumab subcutaneous injection; Vedolizumab-800cw; | [1] D08083 D08083 💬 |
[2] ITGA4, ITGB7 💬 |
Arrhythmogenic right ventricular cardiomyopathy [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
094 [3] 94, 96, 97 💬 |